- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02233101
Oral vs. Intravenous TXA Study Proposal: TJA
Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery.
Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery.
Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.
Background/Scientific review:
Total hip or knee arthroplasty is associated with the risk of moderate to significant blood loss. Techniques such as the use of antifibrinolytics or desmopressin, or normovolaemic haemodilution have been used to reduce the need for allogeneic blood transfusion. Tranexamic acid (TXA) has been used to reduce blood loss and transfusion requirement for total hip and knee arthroplasty, with good results. Approximately one-third of patients undergoing total joint replacement surgery require one to three units of blood postoperatively. Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to control bleeding after total joint replacement. The use of TXA has been shown to significantly reduce the need for blood products during total joint replacement1-4.
There are only a few studies directly comparing outcomes following the use of intravenous tranexamic acid (IVTA) and oral tranexamic acid (OTA) in arthroplasty surgery. In the randomized study by Zohar et al5. OTA (n = 20) was associated with significant allogeneic blood sparing com- pared with controls (n = 20), but not when compared with short- and long-term IVTA regimens. A recent randomized trial comparing OTA (n = 26) with placebo (n = 20) reported significant reductions in blood drained at 24 hours, and in the fall of both Hb and Hct in the OTA group, without any significant difference in the requirement of transfusion6.
Study Design: Prospective, randomized, single-blinded study
Treatment Groups:
- Intravenous TXA Group - 1 gram IV bolus 10 minutes prior to incision
- Oral TXA Group - 3 tablets (1950 mg) oral 2 hours prior to incision
Demographics/Patient Specifics: Age, Sex, ASA score, Weight, Height, Estimated intra-operative blood loss, Intra-operative fluids (crystalloid, colloid), Operative time, Hospitalization days, BMI, Pre-operative PT/INR, Pre-operative PTT, Pre-operative platelet count
Outcome Measurements:
- Post-operative reduction in Hgb - Measure pre-operative Hgb levels and post-operative days 0, 1, 2, and 3 Hgb levels. Among the studies presented, they used different time points to determine the reduction in Hgb. They either used the post-operative 12-hour Hgb, post-operative day 4 Hgb, or the lowest Hgb during the hospitalization. Because we rarely have patients stay until post-operative day 4, we will have to make our measure off a different time period. We have patients get discharged as early as post-operative day 1, so we'll probably have to use the post-operative day 1 Hgb level. We feel a Hgb level difference of >1 g/dL is clinically significant.
- Post-operative reduction in Hematocrit - Measure pre-operative and post-operative days 0, 1, 2, and 3 Hematocrit levels
- Number of units transfused
- Number of patients transfused
- Cost comparison - Cost differences resulted from differences in the blood transfusion rate, length of hospital stay, and management of complications as well as from the cost of the TXA itself
Complications
- DVT or PE
- Return to the OR within 30 days
- Re-admission within 30 days
- Superficial infection
- Deep infection
- Periprosthetic fracture
- Cerebrovascular accident or Transient ischemic attack
- Dislocation
Risks/Benefits
The use of Tranexamic Acid is a standard of care used everyday in both primary and revision surgeries, this includes both oral and intravenous forms of Tranexamic Acid. TXA side effects include of nausea, vomiting and/or diarrhea. Gastrointestinal upset could occur with Oral tranexamic acid.
The only risk involved is the potential for breach of confidentiality and/or privacy. Below is a description of the procedure for maintaining confidentiality. There is no direct benefit to the participants in this study.
Procedures for Maintaining Confidentiality
A breach of confidentiality and/or privacy is a risk of this study. To prevent this, all collected data will be stored electronically in password-protected files to protect patient identity and information. All information will be collected and reviewed by the research team only. Data will be maintained on a password-protected computer that will be accessible only to the study team. No patient identifiers will be maintained in the database.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Any patient scheduled for a primary TKA or cementless THA with epidural/spinal anesthesia
Exclusion Criteria:
- Allergy to TXA, acquired disturbances of color vision, refusal of blood products, pre-op use of anticoagulant therapy within five days before surgery, a history of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA), pregnancy, breastfeeding, major comorbidities (such as severe ischemic heart disease [New York Heart Association Class III or IV], previous myocardial infarction, severe pulmonary disease, renal impairment, or hepatic failure), patients who decline to participate, any patient undergoing a revision TKA, THA or BHR
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oral Tranexamic Acid
Patients will receive either oral or intravenous Tranexamic Acid
|
patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
Other Names:
|
Active Comparator: Intravenous Tranexamic Acid
Patients will receive either oral or intravenous Tranexamic Acid
|
Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Required Blood Transfusion
Time Frame: during or within 24 hours after surgery
|
Patient hemoglobin will be measured during and after surgery for the first 24 hours to determine if a blood transfusion is indicated.
|
during or within 24 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Other Complications
Time Frame: participants will be followed for the duration of hospital stay, an expected average of no more than 30 days
|
Any other complications listed below:
|
participants will be followed for the duration of hospital stay, an expected average of no more than 30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RUSH2233
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Loss After Primary Total Joint Arthroplasty
-
Belfast Health and Social Care TrustCompletedPrimary Total Hip Arthroplasty | Primary Total Knee ArthroplastyUnited Kingdom
-
James A. KeeneyRecruitingPrimary Total Hip Arthroplasty | Primary Total Knee ArthroplastyUnited States
-
Novartis PharmaceuticalsWithdrawnProsthetic Fixation After Cementless Total Hip ArthroplastyChina
-
Rush University Medical CenterMayo ClinicCompletedRevision Total Knee Arthroplasty | Revision Total Hip Arthroplasty | Acute Blood Loss AnemiaUnited States
-
Parc de Salut MarCompletedInfection After Primary Total Knee ArthroplastySpain
-
Hospital for Special Surgery, New YorkCompletedHypotension | Primary Total Hip Arthroplasty | Total Hip Arthroplasty | DatabaseUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruitingPrimary Total Knee ArthroplastyBelgium
-
University of UtahEnrolling by invitationPrimary Total Hip ArthroplastyUnited States
-
Smith & Nephew Orthopaedics AGTerminatedPrimary Total Hip ArthroplastyAustria
-
Smith & Nephew Orthopaedics AGTerminatedPrimary Total Hip ArthroplastyAustria
Clinical Trials on Oral Tranexamic Acid
-
Rush University Medical CenterWithdrawnArthritis | Anemia | Total Knee Arthroplasty | Total Hip ArthroplastyUnited States
-
University of LiegeCompletedArthroplasty Complications | Hemorrhage Postoperative | Total Blood LossBelgium
-
Carlos A Acosta-OlivoCompletedBlood Loss, SurgicalMexico
-
Ain Shams UniversityCompleted
-
London School of Hygiene and Tropical MedicineCompleted
-
Universidad Autonoma de Nuevo LeonCompletedKnee Osteoarthritis | Blood Loss | Blood Clot | Transfusion Related ComplicationMexico
-
Lawrence Charles HookeyQueen's UniversityCompleted
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia
-
Hyloris DevelopmentsRecruitingBleeding From Teeth | Bleeding ProphylaxisSpain, United States, Belgium, Croatia, Hungary, Romania
-
The New England Baptist HospitalUnknownOsteoarthritis | Blood Loss, Surgical | Blood Loss, PostoperativeUnited States